

1
2
3
4
5
6
7 LISA CHONG, et al.,
8 Plaintiffs,
9 v.
10 KIND LLC,
11 Defendant.
12
13

14 Case No. 21-cv-04528-RS
15
16

**ORDER VACATING HEARING AND
REQUESTING FURTHER BRIEFING**

17 Plaintiffs in this putative class action advance claims nearly identical to those alleged in
18 *Minor v. Baker Mills, Inc.*, No. 20-cv-02901 RS, in which the plaintiff is represented by the same
19 firm appearing on behalf of these plaintiffs. In both cases the plaintiffs allege defendants overstate
20 the protein content of their food products. In *Minor*, the defendants' motions to dismiss on
21 preemption and various other grounds were denied, and that matter is presently in briefing for
class certification.

22 Defendant KIND, LLC, moves to dismiss the complaint here, making substantially the
23 same arguments that were presented in *Minor*. KIND offers two basic reasons it believes a
24 different result is now warranted. First, KIND presents an email exchange its counsel had with an
25 FDA employee, which it contends shows the FDA's view on how the regulations should be
26 interpreted supports its position and leads to a conclusion that the claims are preempted or that, at
27 a minimum, the matter should be stayed under the primary jurisdiction doctrine. Second, KIND
28 forthrightly "urges the Court to take a fresh look at the governing FDA regulations."

1 For more than one reason, it appears unlikely the email from the FDA employee supports a
2 different outcome or that this case is otherwise distinguishable from *Minor*. The question,
3 therefore, is whether the conclusion of *Minor* is on sound footing.

4 As reflected in the *Minor* order, the issue had been presented as a choice between
5 calculating protein content under the so-called “nitrogen method,” (as defendants insisted they
6 were expressly permitted to do) or under the so-called “amino acid method” (which plaintiff
7 argued was necessary to avoid giving a misleadingly high number). *Minor* concluded that for
8 purposes of providing “% Daily Value,” the protein content “used to derive that percentage *must*
9 be calculated under the amino acid method.” To support that conclusion, *Minor* cited 21 C.F.R. §
10 101.9(c)(7)(ii) (“The ‘corrected amount of protein (gram) per serving’ . . . is equal to the actual
11 amount of protein (gram) per serving multiplied by the amino acid score corrected for protein
12 digestibility . . .”).

13 Thus, it appears *Minor* may have conflated the so-called “amino acid method” for
14 calculating the grams of protein in a product with the Protein Digestibility Corrected Amino Acid
15 Score (“PDCAAS”). Defendant insists the PDCAAS, which is discussed in FDA regulations, is a
16 fundamentally different thing from the “amino acid method” that plaintiffs allege they used to test
17 the product and that they believe should be required. Plaintiffs seem to agree PDCAAS is not the
18 same as their “amino acid method”—the theory here (and in an amended complaint in *Minor*) is
19 that the protein claims are overstated *both* because of the use of the nitrogen method *and* because
20 of a failure further to adjust for digestibility using PDCAAS.

21 While plaintiffs believe there is still no preemption, it is not clear that the protein content
22 used to derive the “% Daily Value” must be calculated under the amino acid method, as opposed
23 to merely being adjusted for digestibility using PDCAAS. Additionally, there appears to be at least
24 an argument that requiring adjustments for digestibility when calculating “% Daily Value” is not
25 inconsistent with allowing the number of grams of protein, calculated by the nitrogen method, to
26 be stated on the box without such adjustments.


27 Plaintiffs’ current briefing continues to blur the distinctions between the “amino acid
28

1 method" and PDCAAS. At least at this juncture, however, it appears *Minor*'s finding that there
2 was no preemption may rest on a mistaken understanding that the language in 21 C.F.R. §
3 101.9(c)(7)(ii) endorsed use of the amino acid method, as opposed merely to calling for
4 application of PDCAAS.

5 Accordingly, the hearing set for September 30, 2021 is vacated. Within 10 days of the date
6 of this order, plaintiffs may file a supplemental brief, not to exceed 12 pages, addressing these
7 issues. Within a week thereafter, defendant may file a response, also limited to 12 pages. The
8 matter will then be taken under submission, or set for argument, in the court's discretion.
9

10 **IT IS SO ORDERED.**

11 Dated: September 23, 2021
12
13
14



RICHARD SEEBORG
Chief United States District Judge

United States District Court
Northern District of California